A new experimental drug has shown promise in treating influenza, preventing death from the virus, show preclinical studies.
University of Maryland School of Medicine researchers found that a drug called Eritoran could protect mice from death after they have been infected with a lethal dose of influenza virus.
Bird Flu
Bird flu (avian influenza/avian flu) is a disease caused by an influenza virus (H5N1) that primarily affects birds but can infect humans also.
Advertisement
The potential value of this drug as single therapy or in combination with antivirals is further supported by previous research that found that it is safe for use in humans.
The findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China - 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.
![Quiz on Flu]( "Quiz on Flu")
Influenza (or rather, the flu) is a cold weather infectious condition that affects the young and old alike. Though most reported cases are mild, the flu can sometimes cause severe and life-threatening complications in both children and adults, thanks to wrong medications and improper vaccinations. Learn more about the disease from our Flu Quiz and guard yourself and your family from a poss
Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4).
Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality.
In their new study, they extend these findings by showing that Eritoran - a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis - improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus.
Existing antiviral medications must be administered within two days of infection to be optimally effective.
The study was published in the journal Nature.
Source: ANI
Quiz on Flu
Influenza (or rather, the flu) is a cold weather infectious condition that affects the young and old alike. Though most reported cases are mild, the flu can sometimes cause severe and life-threatening complications in both children and adults, thanks to wrong medications and improper vaccinations. Learn more about the disease from our Flu Quiz and guard yourself and your family from a poss
Advertisement
Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4).
Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality.
In their new study, they extend these findings by showing that Eritoran - a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis - improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus.
Existing antiviral medications must be administered within two days of infection to be optimally effective.
The study was published in the journal Nature.
Source: ANI
Molecular Assays That can Speed Up Diagnosis of Influenza Developed
A new study reveals that a team of Dutch scientists has created a set of molecular assays that could be an effective alternative for conventional diagnostic methods.
Advertisement
 Source of H7N9 Avian Influenza IdentifiedResearchers have ascribed H7N9 source to genetic reassortment of wild birds from east Asia and chickens from east China. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.